详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Molecular Biology,Hebei Medical University, Fourth Hospital, Shijiazhuang, People’s Republic of China [2]Department of Obstetrics and Gynaecology,Hebei Medical University, Fourth Hospital, Shijiazhuang, People’s Republic of China [3]Department of Surgical,Hebei Medical University, Fourth Hospital, Shijiazhuang, People’s Republic of China

出处：

DOI：

ISSN：

关键词： Clinical outcome epithelial ovarian cancer ERCC1 meta-analysis platinum chemotherapy polymorphism

摘要：

Background: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC). Methods: A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis. Results: The analysis showed that the AA genotype of the rs3212986C/A polymorphism in ERCC1 was associated with progression-free survival of EOC patients (HR = 1.39, 95% CI = 1.12-1.73) and that the CA or AA genotypes could influence overall survival (HR = 1.28, 95% CI = 1.05-1.56; and HR = 1.55, 95% CI = 1.17 similar to 2.05, respectively). Conclusions: The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.

基金：

基金编号： H2012206164

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2014]版：

大类 | 3 区医学

小类 | 4 区生物工程与应用微生物 4 区毒理学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区生物工程与应用微生物 4 区毒理学

JCR分区：

出版当年[2014]版：

Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 TOXICOLOGY

最新[2023]版：

Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q4 TOXICOLOGY

影响因子： 2 最新[2023版] 2.3 最新五年平均 2.26 出版当年[2014版] 2.263 出版当年五年平均 2.522 出版前一年[2013版] 2.016 出版后一年[2015版]

第一作者：

第一作者机构： [1]Department of Molecular Biology,Hebei Medical University, Fourth Hospital, Shijiazhuang, People’s Republic of China [*1]Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Jiankanglu 12, Shijiazhuang 050011, People’s Republic of China.

通讯作者：

通讯机构： [1]Department of Molecular Biology,Hebei Medical University, Fourth Hospital, Shijiazhuang, People’s Republic of China [*1]Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Jiankanglu 12, Shijiazhuang 050011, People’s Republic of China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]DNA Repair Gene Associated with Clinical Outcome of Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy [2]Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy [3]ERCC1基因多态性与卵巢上皮性癌患者铂类药物化疗敏感性及预后的关系 [4]ERCC1基因多态性对上皮性卵巢癌患者铂类化疗应答和预后的影响 [5]CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer [6]Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer [7]The Associations of Genetic Variants in E-cadherin Gene With Clinical Outcome of Epithelial Ovarian Cancer [8]XPG基因遗传变异与上皮性卵巢癌铂类化疗预后相关性研究 [9]p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China [10]Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes